EIF4E and cancer: However, considering what is found in cancer models, this negative feedback is not activated in early-stage disease, permitting eIF4E and S6K to act on the downstream regulators of mesenchymal cell transition, apoptosis, autophagy, senescence, cell growth, and motility (35).